Advertisement

Oncology

The FDA has approved Pfizer’s talazoparib (Talzenna) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations. The approval was based on the TALAPRO-3 trial of 599 patients, according…

AstraZeneca is building out a portfolio of targeted cancer drugs, and the first pivotal readout from its wholly owned antibody-drug conjugates is a win: sonesitatug vedotin (Sone-Ve) reduced the risk of death by 42% in previously treated advanced gastric cancer…

The shortages of generic chemotherapy drugs that began this spring have outlasted every resupply estimate drugmakers have given, and one major manufacturer now expects disruptions to last into 2028. Four drugs were in short supply in June. By October, the…

Advertisement

Boston-based Dana-Farber Cancer Institute has named Eliezer Van Allen, MD, its inaugural chief AI officer, the cancer center said in an Oct. 23 LinkedIn post. Dr. Van Allen will lead Dana-Farber’s AI strategy, governance and portfolio across its research, clinical,…

New Orleans-based LCMC Health will launch a no-cost genetic screening initiative to help 100,000 adults identify inherited risks for certain cancers and heart disease. The Uniquely You program, in collaboration with genomics company Helix, will allow participants to provide DNA…

Chicago-based Northwestern Medicine has opened an approximately 80,000-square-foot outpatient center on the campus of Huntley, Ill.-based Northwestern Medicine Huntley Hospital, expanding cancer, heart and specialty care services. The facility expands existing oncology and infusion, cardiovascular, general surgery and urology services…

Advertisement